Overview
Shetal Patel is an Oncologist in Chapel Hill, North Carolina. Dr. Patel is rated as an Experienced provider by MediFind in the treatment of Multiple Endocrine Neoplasia Type 1. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Small Cell Lung Cancer (SCLC), ALK-Positive Non-Small Cell Lung Cancer, and Squamous Cell Lung Carcinoma. Dr. Patel is currently accepting new patients.
Her clinical research consists of co-authoring 17 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- MEDICARE MAPD
- MEDICARE SNP
- OTHER MEDICARE
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- INSURANCE PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER COMMERCIAL
- OTHER MEDICARE
- PPO
- OTHER MEDICARE
- OTHER MEDICARE PART D
- EPO
- HMO
- PPO
- HMO
- MEDICARE MAPD
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- OTHER MEDICAID
- STATE MEDICAID
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
101 Manning Dr, Chapel Hill, NC 27514
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
3 Clinical Trials
Duke Cancer Center
Michael Morse is a Hematologist Oncology specialist and an Oncologist in Durham, North Carolina. Dr. Morse has been practicing medicine for over 35 years and is rated as a Distinguished provider by MediFind in the treatment of Multiple Endocrine Neoplasia Type 1. His top areas of expertise are Neuroendocrine Tumor, Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), Appendix Cancer, and Liver Embolization.
Duke Cancer Center
Diane Reidy is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Reidy is rated as an Elite provider by MediFind in the treatment of Multiple Endocrine Neoplasia Type 1. Her top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreatic Cancer, Pancreaticoduodenectomy, and Liver Embolization.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Small Cell Lung Cancer (SCLC)Dr. Patel isDistinguished. Learn about Small Cell Lung Cancer (SCLC).
- Advanced
- ALK-Positive Non-Small Cell Lung Cancer
- Colorectal CancerDr. Patel isAdvanced. Learn about Colorectal Cancer.
- EGFR Positive Lung CancerDr. Patel isAdvanced. Learn about EGFR Positive Lung Cancer.
- Familial Colorectal CancerDr. Patel isAdvanced. Learn about Familial Colorectal Cancer.
- Large-Cell Lung CarcinomaDr. Patel isAdvanced. Learn about Large-Cell Lung Carcinoma.
- Lung AdenocarcinomaDr. Patel isAdvanced. Learn about Lung Adenocarcinoma.
- Experienced
- Acinic Cell Carcinoma of Salivary Glands
- AgranulocytosisDr. Patel isExperienced. Learn about Agranulocytosis.
- Epithelial-Myoepithelial CarcinomaDr. Patel isExperienced. Learn about Epithelial-Myoepithelial Carcinoma.
- GliomaDr. Patel isExperienced. Learn about Glioma.
- Lacrimal Gland TumorDr. Patel isExperienced. Learn about Lacrimal Gland Tumor.
- Laryngeal CancerDr. Patel isExperienced. Learn about Laryngeal Cancer.

